Abstract Search

ea0022p661 | Neuroendocrinology and Pituitary (<emphasis role="italic">Generously supported by Novartis</emphasis>) | ECE2010

SSTR5 ligand binding domain immunohistological detection in pituitary adenomas using Y-SSTR5 a new mouse monoclonal antibody

Rossi Valentina , Staibano Stefania , Del Basso De Caro Laura , Bellastella Giuseppe , Ilardi Gennaro , Cavallo Luigi , Colao Annamaria , Agostino Sinisi Antonio

Polyclonal antibodies against somatostatin receptors (SSTRs) available up to now recognizing intracellular sites of receptors and their recycling products do not detect bioactive ligand binding domains (LBDs) and are of limited performance in paraffin-embedded tissues. Aim of this study was to evaluate by immunohistochemistry the expression of SSTR5 on an archival series of pituitary tumors using a new MoAbs against the SST-binding domain (Y-SSTR5).Metho...

0 shares

ea0016p343 | Endocrine tumours | ECE2008

Raloxifene induces growth arrest and apoptosis in prostate cell lines expressing both ERα and β

Bellastella Giuseppe , Rossi Valentina , Visconti Daniela , Palumbo Vincenzo , Chieffi Paolo , Staibano Stefania , Mascolo Giuseppe , Preziosi Domenico , Bellastella Antonio , Sinisi Antonio Agostino

Raloxifene (RAL) is a selective estrogen receptor (ER) modulator (SERM) proposed for chemoprevention of breast cancer and osteoporosis. SERMs exert agonistantagonist effects depending on tissue or ERs expressed. RAL induces apoptosis in both androgen-dependent and independent cell lines, suggesting a selective activation of ERβ and prevalent antagonist effect on ERα in prostate cells (PC). In this study we evaluated effects of estradiol (E2) and RAL on epitheli...

0 shares

Endocrine Abstracts

SSTR5 ligand binding domain immunohistological detection in pituitary adenomas using Y-SSTR5 a new mouse monoclonal antibody

Raloxifene induces growth arrest and apoptosis in prostate cell lines expressing both ERα and β

BiosciAbstracts